Tenofovir effect on the kidneys of hiv-infected patients: A double-edged sword?

Journal of the American Society of Nephrology

Volumn 24, Issue 10, 2013, Pages 1519-1527

  Tourret, Jérôme ^a   Deray, Gilbert ^a   Isnard Bagnis, Corinne ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; BONE MINERALIZATION; BONE PAIN; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FANCONI RENOTUBULAR SYNDROME; FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NONHUMAN; OSTEOMALACIA; PATHOPHYSIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT OUTCOME;

EID: 84885071926     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012080857     Document Type: Review

References (88)

1. Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treatedwith tenofovir: comparisonwith other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 716-723, 2002
2. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A: Tenofovir nephrotoxicity: 2011 update. Aids Res Treat 2011: 354908, 2011
3. Gilead Science 2006 annual report on marketed products. 2007. Available at: http://www.gilead.ca/AR2006/hiv-aids.php. Accessed September 9, 2013
4. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442-2455, 2008
5. U. S. Food and Drug Administration. Viread. 2008. Modified indication. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 021356s025lb.pdf. Accessed September 9, 2013
6. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF: The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 21: 1273-1281, 2007
7. Atta MG, Fine DM: Editorial comment: tenofovir nephrotoxicity-the disconnect between clinical trials and real-world practice. AIDS Read 19: 118-119, 2009
8. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J: Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis 40: 1331-1333, 2002
9. Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D: Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 17: 935-937, 2003
10. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36: 1070-1073, 2003
11. Rollot F, Nazal EM, Chauvelot-Moachon L, Kélaïdi C, Daniel N, Saba M, Abad S, Blanche P: Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis 37: e174-e176, 2003
12. Breton G, Alexandre M, Duval X, Prie D, Peytavin G, Leport C, Vildei JL: Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 36: 527-528, 2004
13. Callens S, De Roo A, Colebunders R: Fanconilike syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 47: 262-263, 2003
14. Earle KE, Seneviratne T, Shaker J, Shoback D: Fanconi's syndrome inHIV+ adults: Report of three cases and literature review. J Bone Miner Res 19: 714-721, 2004
15. Gaspar G, Monereo A, García-Reyne A, de Guzmán M: Fanconi syndrome and acute renal failure in a patient treated with tenofovir: A call for caution. AIDS 18: 351-352, 2004
16. Haverkort ME, van der SpekBW, Lips P, Slieker WA, Ter Heine R, Huitema AD, Bronsveld W: Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: Role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis
17. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC: Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: A report of 3 cases. AIDS Read 19: 114-121, 2009
18. James CW, Steinhaus MC, Szabo S, Dressier RM: Tenofovir-related nephrotoxicity: Case report and review of the literature. Pharmacotherapy 24: 415-418, 2004
19. Kapitsinou PP, Ansari N: Acute renal failure in an AIDS patient on tenofovir: A case report. J Med Case Reports 2: 94, 2008
20. Malik A, Abraham P, Malik N: Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J Infect 51: E61-E65, 2005
21. Mathew G, Knaus SJ: Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 21: C3-C5, 2006
22. Quimby D, Brito MO: Fanconi syndrome associated with use of tenofovir in HIV-infected patients: A case report and review of the literature. AIDS Read 15: 357-364, 2005
23. Rifkin BS, Perazella MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 117: 282-284, 2004
24. Gupta SK: Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS 22: 99-103, 2008
25. Wever K, van Agtmael MA, Carr A: Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81, 2010
26. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M: Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505, 2010
27. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G; Study 903 Team: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized activecontrolled multicentre study. Nephrol Dial Transplant 20: 743-746, 2005
28. Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, Rachlis A, Loutfy M: Incidence of and risk factors for tenofovirinduced nephrotoxicity: Aretrospective cohort study. HIV Med 6: 284-290, 2005
29. Gayet-AgeronA, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, Le Braz M, Ruxrungtham K, Rooney JF, Hirschel B; Staccato Study Group: No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 59: 1034-1037, 2007
30. Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C: Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther 12: 31-39, 2007
31. Padilla S, Gutiérrez F, Masiá M, Cánovas V, Orozco C: Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the realworld: A case-control study. AIDS Patient Care STDS 19: 421-424, 2005
32. Scott JD, Wolfe PR, Bolan RK, Guyer B: Serious renal impairment occurs rarely with use of tenofovir DF. HIV Clin Trials 7: 55-58, 2006
33. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T; CISAI Group: Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project. Biomed Pharmacother 62: 6-11, 2008
34. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B: Renal dysfunction with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr 37: 1489-1495, 2004
35. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40: 1194-1198, 2005
36. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S: Minor changes in calculated creatinine clearance and aniongap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIVMed 7: 105-111, 2006
37. Mauss S, Berger F, Schmutz G: Antiretroviral therapy with tenofovir is associated withmild renal dysfunction. AIDS 19: 93-95, 2005
38. Menezes AM, Torelly J Jr, Real L, Bay M, Poeta J, Sprinz E: Prevalence and risk factors associated to chronic kidney disease in HIVinfected patients on HAART and undetectable viral load in Brazil. PLoSONE 6: e26042, 2011
39. Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG: Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 4: 327-336, 2008
40. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M: Age- and genderspecific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 72: 632-637, 2007
41. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG: Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26: 867-875, 2012
42. Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N: Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract 25: 552-559, 2012
43. Cotter AG, Powderly WG: Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 25: 501-515, 2011
44. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, Hay PE, Pakianathan MR, Sadiq ST: Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 54: 496-499, 2010
45. Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, Mullen MP, Branch AD: Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 26: 855-859, 2010
46. Masia M, Padilla S, Robledano C, Lopez N, Ramos JM, Gutierrez F: Early changes in parathyroid hormone concentrations in HIVinfected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses 28: 242-246, 2012
47. Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C: Whole body bone scintigraphy in tenofovir-related osteomalacia: A case report. J Med Case Reports 3: 8136, 2009
48. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW: The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 6: 341-346, 2005
49. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C: Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 15: 72-74, 2009
50. Giola M, Basilico C, Grossi P: Fatal lactic acidosis associatedwith tenofovir and abacavir. Int J Infect Dis 9: 228-229, 2005
51. Guo Y, Fung HB: Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 24: 1089-1094, 2004
52. Hansen AB, Mathiesen S, Gerstoft J: Severe metabolic acidosis and renal failure in anHIV-1 patient receiving tenofovir. Scand J Infect Dis 36: 389-392, 2004
53. Rivas P, Polo J, de Górgolas M, Fernández-Guerrero ML: Drug points: Fatal lactic acidosis associated with tenofovir. BMJ 327: 711, 2003
54. Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D: Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. Pediatr InfectDis J 22: 668-670, 2003
55. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P: Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. J Ren Care 37: 25-29, 2011
56. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS: Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78: 1171-1177, 2010
57. Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker UA: Mitochondrial tubulopathy in tenofovir disoproxil fumaratetreated rats. J Acquir Immune Defic Syndr 51: 258-263, 2009
58. Rodriguez-Novoa S, Labarga P, Soriano V: Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10: 1675-1685, 2009
59. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR: Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50: 3297-3304, 2006
60. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W: Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 91: 852-858, 2011
61. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K: Renal transport of adefovir, cidofovir, and tenofovir by SLC22A familymembers (hOAT1, hOAT3, and hOCT2). Pharm Res 24: 811-815, 2007
62. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG: Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194: 1481-1491, 2006
63. Izzedine H, Launay-Vacher V, Deray G: Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45: 804-817, 2005
64. Lewis W, Day BJ, Copeland WC: Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat Rev Drug Discov 2: 812-822, 2003
65. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD: Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 32: 734-740, 2001
66. Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS: Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 11: 79-86, 2006
67. Ortiz A, Justo P, Sanz A, Melero R, Caramelo C, Guerrero MF, Strutz F, Müller G, Barat A, Egido J: Tubular cell apoptosis and cidofovirinduced acute renal failure. Antivir Ther 10: 185-190, 2005
68. Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier MC: Normal plasma FGF23 levels kinetic in tenofovirrelated hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78: 306-308, 2011
69. Libório AB, Andrade L, Pereira LV, Sanches TR, Shimizu MH, Seguro AC: Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int 74: 910-918, 2008
70. Rodríguez-Nóvoa S, Labarga P, D'avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di Perri G, Soriano V: Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 24: 1064-1066, 2010
71. Poizot-Martin I, Solas C, Allemand JO-RBrégigeon S, Ménard A, Faucher O, Lacarelle B, Brégigeon S, Ménard A, Faucher O, Lacarelle B, editors. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir concentration? Conference on Retroviruses and Opportunistic Infections (CROI); 2011; Boston.
72. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S: Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: A retrospective cohort study of Japanese patients. PLoS ONE 6: e22661, 2011
73. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G: Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 42: 283-290, 2006
74. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM: Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21: 1431-1439, 2007
75. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S; California Collaborative Treatment Group 578 Team: Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 197: 102-108, 2008
76. Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, Roy A, Rhodes GR: Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 12: 267-272, 2007
77. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV: The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83: 265-272, 2008
78. Ray AS, Wright MR, Rhodes GR: Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. Clin Pharmacol Ther 84: 660, author reply 661, 2008
79. Buchacz K, Young B, Baker RK, Moorman A, Chmiel JS, Wood KC, Brooks JT: Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr 43: 626-628, 2006
80. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sánchez de la Rosa R, Giralt M, Alvarez ML, López-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P: In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 50: 3824-3832, 2006
81. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, González-Pardo G, Khoo S, Back D, Owen A: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study. Clin Infect Dis 48: e108-e116, 2009
82. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV: Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47: 298-303, 2008
83. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA: Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 1559-1585, 2005
84. European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185, 2012
85. Lake JE, Adams JS: Vitamin D in HIV-infected patients. Curr HIV/AIDS Rep 8: 133-141, 2011
86. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M: Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: A case of drug-drug interaction. Clin Nephrol 71: 567-570, 2009
87. Psevdos G Jr, Gonzalez E, Sharp V: Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read 19: 245-248, 2009
88. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402, 2012